

Indolent Lymphoma: Epidemiology Forecasting Intelligence

<https://marketpublishers.com/r/IC997DD47F8EN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: IC997DD47F8EN

Abstracts

CmaxInsight's "Indolent Lymphoma-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Indolent Lymphoma epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

- Incidence and prevalence

- Diagnosis rate, treatment rate and mortality patterns

- Epidemiology-based forecasting and disease trends

- Size of different patient segments in a disease area

- Population based: disease occurrence, co-morbidities and treatment patterns

- Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment

Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.

Contents

1. REPORT INTRODUCTION

2. INDOLENT LYMPHOMA EPIDEMIOLOGY OVERVIEW AT A GLANCE

3. MARKET SHARE DISTRIBUTION OF INDOLENT LYMPHOMA

4. DISEASE BACKGROUND AND OVERVIEW: INDOLENT LYMPHOMA

4.1. Introduction

4.2. Signs and Symptoms

4.3. Etiology

4.4. Risk Factors

4.5. Pathophysiology

4.6. Diagnostic Landscape

4.6.1. Diagnostic Practices

4.6.2. Diagnostic Criteria

4.6.3. Diagnostic Recommendations

4.7. Treatment Landscape

4.7.1. Current Treatment Practices

4.7.2. Treatment Algorithm

4.7.3. Treatment Recommendations

5. INDOLENT LYMPHOMA EPIDEMIOLOGY

5.1. Key Findings

5.2. Assumptions & Rationale

5.3. 7MM Epidemiology

6. EPIDEMIOLOGY OF INDOLENT LYMPHOMA BY COUNTRIES

7. UNITED STATES

7.1. Assumptions and Rationale

7.2. Prevalent/Incident Cases of Indolent Lymphoma

7.3. Sub-Type Specific cases of Indolent Lymphoma*

7.4. Sex- Specific Cases of Indolent Lymphoma*

7.5. Diagnosed Cases of Indolent Lymphoma

7.6. Treated Cases of Indolent Lymphoma

8. EU5

8.1. Germany

- 8.1.1. Assumptions and Rationale
- 8.1.2. Prevalent/Incident Cases of Indolent Lymphoma
- 8.1.3. Sub-Type Specific cases of Indolent Lymphoma*
- 8.1.4. Sex- Specific Cases of Indolent Lymphoma*
- 8.1.5. Diagnosed Cases of Indolent Lymphoma
- 8.1.6. Treated Cases of Indolent Lymphoma

8.2. France

- 8.2.1. Assumptions and Rationale
- 8.2.2. Prevalent/Incident Cases of Indolent Lymphoma
- 8.2.3. Sub-Type Specific cases of Indolent Lymphoma*
- 8.2.4. Sex- Specific Cases of Indolent Lymphoma*
- 8.2.5. Diagnosed Cases of Indolent Lymphoma
- 8.2.6. Treated Cases of Indolent Lymphoma

8.3. United Kingdom

- 8.3.1. Assumptions and Rationale
- 8.3.2. Prevalent/Incident Cases of Indolent Lymphoma
- 8.3.3. Sub-Type Specific cases of Indolent Lymphoma*
- 8.3.4. Sex- Specific Cases of Indolent Lymphoma*
- 8.3.5. Diagnosed Cases of Indolent Lymphoma
- 8.3.6. Treated Cases of Indolent Lymphoma

8.4. Spain

- 8.4.1. Assumptions and Rationale
- 8.4.2. Prevalent/Incident Cases of Indolent Lymphoma
- 8.4.3. Sub-Type Specific cases of Indolent Lymphoma*
- 8.4.4. Sex- Specific Cases of Indolent Lymphoma*
- 8.4.5. Diagnosed Cases of Indolent Lymphoma
- 8.4.6. Treated Cases of Indolent Lymphoma

8.5. Italy

- 8.5.1. Assumptions and Rationale
- 8.5.2. Prevalent/Incident Cases of Indolent Lymphoma
- 8.5.3. Sub-Type Specific cases of Indolent Lymphoma*
- 8.5.4. Sex- Specific Cases of Indolent Lymphoma*
- 8.5.5. Diagnosed Cases of Indolent Lymphoma
- 8.5.6. Treated Cases of Indolent Lymphoma

9. JAPAN

- 9.1. Assumptions and Rationale
- 9.2. Prevalent/Incident Cases of Indolent Lymphoma
- 9.3. Sub-Type Specific cases of Indolent Lymphoma*
- 9.4. Sex- Specific Cases of Indolent Lymphoma*
- 9.5. Diagnosed Cases of Indolent Lymphoma
- 9.6. Treated Cases of Indolent Lymphoma

10. UNMET NEEDS

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM
Table 2: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Indolent Lymphoma in United States
Table 4: Sub-Type Specific Cases of the Indolent Lymphoma in United States*
Table 5: Sex- Specific Cases of the Indolent Lymphoma in United States*
Table 6: Diagnosed Cases of the Indolent Lymphoma in United States
Table 7: Treated Cases of the Indolent Lymphoma in United States
Table 8: Prevalent/Incident Cases of the Indolent Lymphoma in Germany
Table 9: Sub-Type Specific Cases of the Indolent Lymphoma in Germany*
Table 10: Sex- Specific Cases of the Indolent Lymphoma in Germany*
Table 11: Diagnosed Cases of the Indolent Lymphoma in Germany
Table 12: Treated Cases of the Indolent Lymphoma in Germany
Table 13: Prevalent/Incident Cases of the Indolent Lymphoma in France
Table 14: Sub-Type Specific Cases of the Indolent Lymphoma in France*
Table 15: Sex- Specific Cases of the Indolent Lymphoma in France*
Table 16: Diagnosed Cases of the Indolent Lymphoma in France
Table 17: Treated Cases of the Indolent Lymphoma in France
Table 18: Prevalent/Incident Cases of the Indolent Lymphoma in Italy
Table 19: Sub-Type Specific Cases of the Indolent Lymphoma in Italy*
Table 20: Sex- Specific Cases of the Indolent Lymphoma in Italy*
Table 21: Diagnosed Cases of the Indolent Lymphoma in Italy
Table 22: Treated Cases of the Indolent Lymphoma in Italy
Table 23: Prevalent/Incident Cases of the Indolent Lymphoma in Spain
Table 24: Sub-Type Specific Cases of the Indolent Lymphoma in Spain*
Table 25: Sex- Specific Cases of the Indolent Lymphoma in Spain*
Table 26: Diagnosed Cases of the Indolent Lymphoma in Spain
Table 27: Treated Cases of the Indolent Lymphoma in Spain
Table 28: Prevalent/Incident Cases of the Indolent Lymphoma in UK
Table 29: Sub-Type Specific Cases of the Indolent Lymphoma in UK*
Table 30: Sex- Specific Cases of the Indolent Lymphoma in UK*
Table 31: Diagnosed Cases of the Indolent Lymphoma in UK
Table 32: Treated Cases of the Indolent Lymphoma in UK
Table 33: Prevalent/Incident Cases of the Indolent Lymphoma in Japan
Table 34: Sub-Type Specific Cases of the Indolent Lymphoma in Japan*
Table 35: Sex- Specific Cases of the Indolent Lymphoma in Japan*

Table 36: Diagnosed Cases of the Indolent Lymphoma in Japan

Table 37: Treated Cases of the Indolent Lymphoma in Japan

*Indication Specific

List Of Figures

LIST OF FIGURES

- Figure 1: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM
- Figure 2: Total Prevalent/Incident Cases of the Indolent Lymphoma in 7MM by Countries
- Figure 3: Prevalent/Incident Cases of the Indolent Lymphoma in United States
- Figure 4: Sub-Type Specific Cases of the Indolent Lymphoma in United States*
- Figure 5: Sex- Specific Cases of the Indolent Lymphoma in United States*
- Figure 6: Diagnosed Cases of the Indolent Lymphoma in United States
- Figure 7: Treated Cases of the Indolent Lymphoma in United States
- Figure 8: Prevalent/Incident Cases of the Indolent Lymphoma in Germany
- Figure 9: Sub-Type Specific Cases of the Indolent Lymphoma in Germany*
- Figure 10: Sex- Specific Cases of the Indolent Lymphoma in Germany*
- Figure 11: Diagnosed Cases of the Indolent Lymphoma in Germany
- Figure 12: Treated Cases of the Indolent Lymphoma in Germany
- Figure 13: Prevalent/Incident Cases of the Indolent Lymphoma in France
- Figure 14: Sub-Type Specific Cases of the Indolent Lymphoma in France*
- Figure 15: Sex- Specific Cases of the Indolent Lymphoma in France*
- Figure 16: Diagnosed Cases of the Indolent Lymphoma in France
- Figure 17: Treated Cases of the Indolent Lymphoma in United France
- Figure 18: Prevalent/Incident Cases of the Indolent Lymphoma in Italy
- Figure 19: Sub-Type Specific Cases of the Indolent Lymphoma in Italy*
- Figure 20: Sex- Specific Cases of the Indolent Lymphoma in Italy*
- Figure 21: Diagnosed Cases of the Indolent Lymphoma in Italy
- Figure 22: Treated Cases of the Indolent Lymphoma in Italy
- Figure 23: Prevalent/Incident Cases of the Indolent Lymphoma in Spain
- Figure 24: Sub-Type Specific Cases of the Indolent Lymphoma in Spain*
- Figure 25: Sex- Specific Cases of the Indolent Lymphoma in Spain*
- Figure 26: Diagnosed Cases of the Indolent Lymphoma in Spain
- Figure 27: Treated Cases of the Indolent Lymphoma in Spain
- Figure 28: Prevalent/Incident Cases of the Indolent Lymphoma in UK
- Figure 29: Sub-Type Specific Cases of the Indolent Lymphoma in UK*
- Figure 30: Sex- Specific Cases of the Indolent Lymphoma in UK*
- Figure 31: Diagnosed Cases of the Indolent Lymphoma in UK
- Figure 32: Treated Cases of the Indolent Lymphoma in UK
- Figure 33: Prevalent/Incident Cases of the Indolent Lymphoma in Japan
- Figure 34: Sub-Type Specific Cases of the Indolent Lymphoma in Japan*

Figure 35: Sex- Specific Cases of the Indolent Lymphoma in Japan*

Figure 36: Diagnosed Cases of the Indolent Lymphoma in Japan

Figure 37: Treated Cases of the Indolent Lymphoma in Japan

*Indication Specific

I would like to order

Product name: Indolent Lymphoma: Epidemiology Forecasting Intelligence

Product link: <https://marketpublishers.com/r/IC997DD47F8EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IC997DD47F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970